Q3 2024 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2024-11-15 · accession 0001892134-24-000006
$2.50B
Reported value
53
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $256.2M | 10.3% | 6,570,392 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $213.4M | 8.55% | 12,855,194 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $182.8M | 7.33% | 10,109,279 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $179.9M | 7.21% | 988,460 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $155.5M | 6.23% | 5,985,347 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $126.6M | 5.08% | 2,416,952 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $100.5M | 4.03% | 879,405 | Common | SOLE |
| 925050106 | VRNA | VERONA PHARMA PLC | $97.4M | 3.90% | 3,383,950 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $95.7M | 3.84% | 3,760,457 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $86.2M | 3.46% | 1,754,834 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $81.7M | 3.27% | 8,785,284 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $75.6M | 3.03% | 2,832,867 | Common | SOLE |
| 032724106 | ANAB | ANAPTYSBIO INC | $74.0M | 2.97% | 2,209,189 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $52.9M | 2.12% | 19,391,687 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $52.2M | 2.09% | 1,587,527 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $46.4M | 1.86% | 1,044,154 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $45.2M | 1.81% | 997,455 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $44.2M | 1.77% | 875,667 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $42.7M | 1.71% | 3,687,867 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $42.5M | 1.70% | 4,142,855 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $35.2M | 1.41% | 633,715 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $34.6M | 1.39% | 8,157,385 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $29.1M | 1.16% | 770,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $27.4M | 1.10% | 1,485,630 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $24.7M | 0.99% | 7,381,090 | Common | SOLE |
| 589492107 | MREO | MEREO BIOPHARMA GROUP PLC | $21.0M | 0.84% | 5,097,779 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $20.9M | 0.84% | 1,148,591 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $19.9M | 0.80% | 133,333 | Common | SOLE |
| 43157M102 | — | HILLEVAX INC | $18.7M | 0.75% | 10,617,062 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $18.6M | 0.75% | 373,100 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $17.2M | 0.69% | 731,020 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $16.8M | 0.67% | 4,623,324 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $16.1M | 0.65% | 576,129 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $15.5M | 0.62% | 1,354,711 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $11.7M | 0.47% | 477,327 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $11.3M | 0.45% | 1,250,786 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $10.2M | 0.41% | 1,892,547 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $10.1M | 0.41% | 936,576 | Common | SOLE |
| 556099109 | MGNX | MACROGENICS INC | $9.9M | 0.40% | 3,010,727 | Common | SOLE |
| 23954D109 | DAWNGBX | DAY ONE BIOPHARMACEUTICALS I | $9.6M | 0.39% | 689,655 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $8.0M | 0.32% | 2,867,750 | Common | SOLE |
| 74587V107 | PBYI | PUMA BIOTECHNOLOGY INC | $7.8M | 0.31% | 3,062,558 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $7.5M | 0.30% | 1,069,244 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $7.4M | 0.30% | 1,000,000 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $7.2M | 0.29% | 470,338 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS INC | $7.0M | 0.28% | 285,331 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $6.0M | 0.24% | 702,694 | Common | SOLE |
| 28623U101 | — | ELEVATION ONCOLOGY INC | $3.6M | 0.14% | 5,993,579 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $3.5M | 0.14% | 500,333 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $3.4M | 0.14% | 108,762 | Common | SOLE |
| 67080N101 | NUVB | NUVATION BIO INC | $2.8M | 0.11% | 1,218,236 | Common | SOLE |
| 00461U105 | ACRS | ACLARIS THERAPEUTICS INC | $304,034 | 0.01% | 264,377 | Common | SOLE |
| 720795202 | — | PIERIS PHARMACEUTICALS INC | $266,869 | 0.01% | 15,942 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.